Go Pro
NASDAQ:NCNA

NuCana Q3 2025 Earnings Report

NuCana logo
$1.09 -0.08 (-6.50%)
As of 02:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NuCana EPS Results

Actual EPS
-$0.10
Consensus EPS
-$2.69
Beat/Miss
Beat by +$2.59
One Year Ago EPS
N/A

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NuCana Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

NuCana's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

NuCana Earnings Headlines

My next big call (under $1)
Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 13 years, with an average gain close to 19%. And this year may be setting up better than most. Bitcoin just strung together its first positive August and September since at least 2013. Historically, when September finished green, October followed with a gain four times out of five. History isn't a guarantee. But I pay attention when the calendar and the momentum line up.tc pixel
NuCana plc Sponsored ADR
NuCana Appoints Ian Webster as Chief Financial Officer
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments designed to improve the delivery and activity of nucleoside analog medicines. The company’s proprietary ProTide technology is intended to help overcome biological barriers that can limit the effectiveness of conventional nucleoside-based therapies.

NuCana’s lead investigational product, NUC-3373, is a ProTide-based therapy derived from 5-fluorouracil (5-FU), a commonly used chemotherapy agent. The company has evaluated NUC-3373 in clinical studies involving patients with advanced solid tumors, including colorectal cancer. NuCana has also developed NUC-7738, an investigational ProTide compound derived from the nucleoside analog 3'-deoxyadenosine, for potential use in oncology and immuno-oncology applications.

NuCana was founded in the United Kingdom and has conducted research and clinical development activities through international collaborations and studies. The company has been led by Chief Executive Officer Hugh Griffith, one of its founders. Its development programs remain focused on advancing novel cancer therapies through clinical testing and potential regulatory approval.

View NuCana Profile